Las Vegas, NV -- (SBWIRE) -- 12/30/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more. EquityObserver.com issues a special report on the following stocks:Rexahn Pharmaceuticals, Inc.(NYSEMKT:RNN),Gevo, Inc.(NASDAQ:GEVO),Eagle Bulk Shipping Inc.(NASDAQ:EGLE),ImmunoCellular Therapeutics Ltd(NYSEMKT:IMUC)
Rexahn Pharmaceuticals, Inc.(NYSEMKT:RNN)managed to keep its gain at 3.32% on above-normal volume of 3.06Mshares. The stock settled at $0.517, after floating in a range of $0.49 - 0.53. Its latest price has reached market capitalization of $75.79M. Its 52-week range has been $0.28 - 0.66. Rexahn Pharmaceuticals, Inc. (Rexahn) is a development-stage biopharmaceutical company. The Company focuses on the development of cures for cancer to patients worldwide.
How Should Investors Trade RNN Now?Don’t Miss out a Special Trend Analysis
Gevo, Inc.(NASDAQ:GEVO)trading on a volume of 3.04Mshares, higher than its standard daily volume. Shares have been closed at$1.39. Over the last twelve months, the stock has lost-10.32% and faced a worst price of $1.12.Gevo, Inc., is a renewable chemicals and advanced biofuels company.
Is GEVO a Solid Investment at These Levels?Read This Report for Details
Eagle Bulk Shipping Inc.(NASDAQ:EGLE)is down at $4.34 on above- normal volume of 2.56Mshares during the last trading day. The stock has its 12-month range $1.43 - 8.75. Its Intraday range is $4.25 - 4.93.Eagle Bulk Shipping Inc. is engaged primarily in the ocean transportation of a range of major and minor bulk cargoes, including iron ore, coal, grain, cement and fertilizer.
How Should Investors Trade EGLE Now?Don’t Miss out a Special Trend Analysis
In the last trading day, ImmunoCellular Therapeutics Ltd(NYSEMKT:IMUC)is on low volume, trading at a volume of versus its average daily volume ratio 2.52M/3.94M shares. At $1.03, the stock has attained market capitalization of 58.81M.ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company.
Will Investors Buy IMUC After Reading This News?Just Go Here and Find Out
About Equity Observer
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/ employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimer at: http://www.equityobserver.com/disclaimer-2/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)